Study guide
19.3 Gout & Calcium Pyrophosphate Deposition Disease
MRCP UK
Track your progress as you read
Finished sections get a check mark.
1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy
1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique
2 Clinical Sciences: Cellular, Genetic & Molecular Medicine
2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders
3 Clinical Sciences: Anatomy, Physiology & Immunology
3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions
4 Clinical Sciences: Statistics, Epidemiology & Trial Design
4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification
5 Clinical Pharmacology, Therapeutics & Toxicology
5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols
6 Cardiology: Coronary Artery Disease & Heart Failure
6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation
7 Cardiology: Arrhythmias, Valvular & Pericardial Disease
7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases
8 Respiratory Medicine: Airway & Parenchymal Lung Disease
8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis
9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders
9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing
10 Gastroenterology: Luminal Gastrointestinal Disease
10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia
11 Gastroenterology: Liver, Biliary & Pancreatic Disease
11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis
12 Endocrinology & Diabetes: Diabetes & Thyroid
12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules
13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium
13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease
14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease
14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases
15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance
15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis
16 Neurology: Cerebrovascular, Headache & Demyelinating Disease
16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases
17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease
17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders
18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease
18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies
19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy
19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease
20 Infectious Diseases & Tropical Medicine
20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites
21 Haematology: Anaemias & Red Cell Disorders
21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease
22 Haematology: Malignancy, Coagulation & Transfusion Medicine
22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions
23 Psychiatry in General Medicine
23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law
24 Geriatric Medicine
24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers
25 Dermatology
25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy
26 Oncology & Palliative Medicine
26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control
27 Medical Ophthalmology
27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease
19.3 Gout & Calcium Pyrophosphate Deposition Disease
Key Takeaways Explain This Topic AI
Gout crystals are needle-shaped with negative birefringence; calcium pyrophosphate crystals are rhomboid with positive birefringence.
Allopurinol is titrated to a serum urate below 360 micromol/L, or below 300 micromol/L in tophaceous or severe disease, with prophylactic colchicine during initiation.
Calcium pyrophosphate deposition disease is associated with haemochromatosis, hyperparathyroidism, hypophosphatasia and hypomagnesaemia - the metabolic causes worth screening in young patients.
Last updated: September 2026
7. Crystal Arthropathies: Gout
Gout is a metabolic disorder characterized by the extracellular deposition of monosodium urate (MSU) monohydrate crystals in synovial fluid, articular cartilage, and soft tissues following chronic hyperuricaemia.
Pathophysiology of Hyperuricaemia
Serum urate saturation threshold in human plasma at 37 °C is 408 µmol/L (6.8 mg/dL) ; above this concentration, plasma is supersaturated, driving nucleated crystallization.
Renal Underexcretion (90% of Patients): Defective renal tubular clearance of urate via URAT1, GLUT9, and OAT4 transporters. Exacerbated by chronic kidney disease, volume depletion, and pharmacological agents that inhibit tubular urate excretion: thiazide and loop diuretics , low-dose aspirin (< 2 g/day), ciclosporin, tacrolimus, pyrazinamide, and ethambutol. Alcohol (particularly beer rich in guanosine purines) generates lactic acid, which competitively inhibits proximal tubular urate secretion.
Metabolic Overproduction (10% of Patients): Increased purine nucleotide degradation or turnover: myeloproliferative and lymphoproliferative neoplasms, cytotoxic chemotherapy ( tumour lysis syndrome ), extensive psoriasis, and rare X-linked enzyme deficiencies ( hypoxanthine-guanine phosphoribosyltransferase [HGPRT] deficiency / Lesch-Nyhan syndrome , or phosphoribosylpyrophosphate [PRPP] synthetase superactivity).
Inflammasome Activation: Free MSU crystals are phagocytosed by synovial resident macrophages, activating the intracellular NLRP3 inflammasome . This activates caspase-1, triggering massive cleavage and secretion of active interleukin-1-beta (IL-1β) . IL-1β drives intense neutrophil recruitment into the joint space, releasing lysosomal proteases and reactive oxygen species.
Clinical Features & Radiography
Acute Gout Attack: Excruciatingly painful, explosive inflammatory monoarthritis that reaches peak intensity within 6 to 12 hours . The joint is intensely erythematous, swollen, warm, and exquisitely tender (even light contact with bedsheets is unbearable). Overlying skin exhibits desquamation as inflammation subsides.
Predilection: > 50–70% of initial attacks involve the first metatarsophalangeal (MTP) joint ( podagra ). Other sites: midfoot (tarsal joints), ankle, knee, and olecranon bursa.
Chronic Tophaceous Gout: Untreated chronic hyperuricaemia leads to the formation of tophi —large, painless or destructive nodular aggregate deposits of monosodium urate crystals surrounded by foreign-body giant cell granulomas. Common locations: helix and antihelix of the ear , olecranon bursae, prepatellar bursae, Achilles tendons, and interphalangeal joints. Tophi can ulcerate through skin, extruding a white, gritty, chalk-like paste.
Radiography: Early attacks show only soft tissue swelling. Chronic tophaceous disease displays pathognomonic punched-out, well-circumscribed marginal or juxta-articular bone erosions with sclerotic borders and "overhanging margins" (Martel's sign / rat-bite erosions) . Joint space is preserved until very late stage, and periarticular osteopenia is absent.
Arthrocentesis (The Gold Standard): Polarized light microscopy of aspirated synovial fluid demonstrates pathognomonic needle-shaped monosodium urate crystals exhibiting strong negative birefringence . Under a compensated polarized light microscope with a red compensator: crystals lying parallel to the axis of the compensator appear bright yellow ("yellow parallel"); crystals lying perpendicular appear blue .
Serum Urate Trap: Serum urate levels may be completely normal or falsely low during an acute gout flare (in up to 30–40% of cases), driven by systemic IL-6-mediated renal uricosuria and cortisol release. Therefore, a normal serum urate during an acute flare does not rule out gout; levels should be repeated 2 to 4 weeks after complete resolution of the attack. Polarized Light Crystal Microscopy
- |
- +-----------------------------------+-----------------------------------+
- | |
- 1. Gout: Monosodium Urate (MSU) 2. Pseudogout: Calcium Pyrophosphate (CPPD)
- Morphology: Needle-shaped, pointed ends - Morphology: Rhomboid-shaped, rectangular/rod
- Birefringence: STRONGLY NEGATIVE - Birefringence: WEAKLY POSITIVE
- Parallel to compensator axis: YELLOW - Parallel to compensator axis: BLUE
- Perpendicular to compensator: BLUE - Perpendicular to compensator: YELLOW
- Acute Attack Management
First-Line Options:
NSAIDs: Rapid, high-dose oral NSAIDs (e.g. naproxen 500 mg BD, or indomethacin) co-prescribed with a proton-pump inhibitor. First-line in young patients without comorbidities.
Colchicine: Oral colchicine 500 micrograms twice to three times daily. Binds tubulin, inhibiting microtubule polymerization and blocking neutrophil chemotaxis and NLRP3 inflammasome activation. Adverse effects: dose-dependent diarrhoea, nausea, vomiting. Requires dose reduction in CKD.
Oral Corticosteroids: Oral prednisolone 30–35 mg daily for 5 days. Treatment of choice in patients with chronic kidney disease, congestive heart failure, active peptic ulcer disease, or anticoagulation , where NSAIDs and colchicine are contraindicated.
Intra-Articular Corticosteroid Injection: Highly effective for large accessible joints (knee) once septic arthritis is definitively excluded.
CRITICAL EXAM RULE: DO NOT initiate or discontinue allopurinol or other urate-lowering therapy during an acute gout flare! Rapid fluctuations in serum urate destabilize established intra-articular tophi, precipitating crystal shedding and dramatically prolonging the attack. If a patient is already taking established allopurinol prior to the flare, continue it at the same dose and treat the acute attack with NSAIDs, colchicine, or steroids.
Long-Term Urate-Lowering Therapy (ULT)
Indications: Recurrent acute attacks (>= 2 attacks within 12 months), presence of tophi, chronic kidney disease (stage 2–5), history of uric acid urolithiasis, or radiographic evidence of joint erosions. Under modern UK (NICE NG219) guidelines, ULT can be offered to anyone after their first attack using shared decision-making.
Timing: Initiate ULT 2 to 4 weeks after complete resolution of an acute flare .
First-Line Agent: Allopurinol —a purine analog that competitively inhibits xanthine oxidase , preventing the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Dosing Protocol: Start low at 100 mg daily (50 mg daily if eGFR < 30 mL/min) and titrate upwards by 100 mg every 2 to 4 weeks until the target serum urate level is achieved.
Target Serum Urate: < 360 µmol/L (< 6.0 mg/dL) for uncomplicated gout; tighten to < 300 µmol/L (< 5.0 mg/dL) for severe tophaceous gout, frequent flares, or persistent erosive disease to promote active crystal dissolution.
Prophylaxis Against Mobilization Flares: Dissolving crystal surface architecture triggers secondary acute flares during ULT titration. Therefore, mandatory co-prescription of low-dose colchicine (500 micrograms once or twice daily) or low-dose NSAID for 3 to 6 months is required when starting allopurinol.
Pharmacogenomics: Screen for the HLA-B*5801 allele in patients of Han Chinese, Korean, or Thai descent before starting allopurinol; HLA-B*5801 positivity confers a massive risk of Allopurinol Hypersensitivity Syndrome (Stevens-Johnson syndrome / toxic epidermal necrolysis) .
Second-Line Agent: Febuxostat —a potent non-purine selective inhibitor of xanthine oxidase. Used when allopurinol is not tolerated or contraindicated. No dose adjustment needed in mild-to-moderate CKD.
Uricosuric Agents: Sulfinpyrazone, probenecid, benzbromarone. Inhibit URAT1 in proximal renal tubules, increasing urinary urate clearance. Ineffective if eGFR < 30 mL/min; contraindicated in nephrolithiasis.
Recombinant Uricase (Pegloticase): Pegylated mammalian uricase that enzymatically converts insoluble uric acid into highly soluble allantoin; reserved for severe, refractory, eroding tophaceous gout.
8. Crystal Arthropathies: Pseudogout (CPPD Deposition Disease)
Calcium pyrophosphate dihydrate (CPPD) crystal deposition disease involves the precipitation of CPPD crystals in articular hyaline cartilage and fibrocartilage ( chondrocalcinosis ).
Clinical Manifestations
Acute CPPD Crystal Arthritis (Pseudogout): Acute, inflammatory monoarthritis or oligoarthritis mimicking gout or septic arthritis. Reaches peak intensity over 12–24 hours.
Joint Distribution: Strongly predilects large joints, with the knee involved in > 50% of acute attacks , followed by the wrist (specifically the radiocarpal joint and triangular fibrocartilage complex [TFCC]), shoulder, ankle, and symphysis pubis. (In stark contrast to gout, pseudogout rarely affects the 1st MTP joint).
Crowned Dens Syndrome: CPPD crystal deposition around the odontoid process (dens) of C2 and the transverse ligament of the atlas; manifests as severe acute neck pain, occipital headache, neck stiffness, and high inflammatory markers in elderly patients, frequently misdiagnosed as temporal arteritis or meningitis.
Polarized Microscopy & Radiography
Polarized Microscopy: Synovial fluid aspiration reveals rhomboid-shaped, rod-shaped, or rectangular crystals exhibiting WEAK POSITIVE BIREFRINGENCE . When aligned parallel to the slow axis of the red compensator, crystals appear blue ; when perpendicular , they appear yellow (the exact inverse of monosodium urate!).
Radiographic Chondrocalcinosis: Plain radiography demonstrates thin, punctate, linear radiodense opacifications within articular hyaline cartilage or fibrocartilage: classically within the menisci of the knee , the triangular fibrocartilage complex (TFCC) of the wrist , and the symphysis pubis .
Secondary Metabolic Associations (The 4 Hs)
While primary CPPD is common in the elderly (> 80 years) due to age-related chondrocyte cartilage degeneration, any presentation in a patient < 60 years mandates an exhaustive metabolic evaluation for secondary predisposing disorders:
Haemochromatosis: Iron overload mutates the HFE gene (C282Y homozygosity). Excess intra-articular ferric ions inhibit pyrophosphatase, promoting CPPD deposition. Classically causes arthropathy of the 2nd and 3rd metacarpophalangeal (MCP) joints with characteristic hook-like osteophytes .
Hyperparathyroidism (Primary): Hypercalcaemia and elevated PTH enhance calcium pyrophosphate nucleation.
Hypomagnesaemia: Magnesium is an essential cofactor for alkaline phosphatase and pyrophosphatases; low magnesium impedes crystal dissolution. Common in Gitelman's syndrome, chronic alcohol use, or loop diuretic therapy.
Hypophosphatasia: Rare autosomal recessive loss-of-function mutation in tissue-nonspecific alkaline phosphatase (ALPL).
Other Associations: Wilson's disease, acromegaly.
Diagnostic Screening Workup in < 60y: Serum ferritin and transferrin saturation, serum calcium, phosphate, magnesium, PTH, alkaline phosphatase, and liver function tests.
Management of Pseudogout
Acute Attack: Joint aspiration and intra-articular corticosteroid injection (highly effective); oral NSAIDs; short course of oral colchicine (500 micrograms twice daily) or oral corticosteroids.
Prophylaxis: Low-dose oral colchicine (500 micrograms once or twice daily) for frequent recurrent attacks.
Crucial Contrast: Unlike gout, there is no disease-modifying urate-lowering equivalent that dissolves CPPD crystals once deposited.